Navigation Links
S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
Date:12/2/2009

of pharmacodynamic (PD) biomarker assays for SB1518 will be presented in a poster, demonstrating PD target efficacy of SB1518 in animal tumor models, as well as, in patients in ongoing Phase 1 clinical studies for advanced leukemias, myeloproliferative diseases and lymphoma. The fourth poster will highlight the effects of SB1518 on ex vivo expanded polycythemia vera (PV) erythroid progenitors which correlate with clinical observations.

Poster No.: 3905, Time: 6-8 p.m. CST, Monday, Dec. 7, 2009, Location: Hall E (Ernest N. Morial Convention Center)

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis

SB1518, which is a potent ATP-competitive inhibitor of JAK2 (IC50=22nM), JAK2V617F mutant (IC50=19nM), FLT3 (IC50=22nM) and its mutant D835Y (IC50=6nM), is being tested to determine its safety, tolerability and PK/PD profile when administered orally once daily continuously in 28-day cycles. SB1518 was well tolerated at doses up to 500 mg daily in patients with advanced myelofibrosis (MF) and acute myelogenous leukemias (AML), and shows clinical activity in MF patients with splenomegaly.

Oral Presentation Abstract No.: 588, Time: 4 p.m. CST, Monday, Dec. 7, 2009, Location: Room R02-R05

Phase 1 Study of the Novel Oral JAK2 Inhibitor SB1518 in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity

A Phase 1 dose escalating study of the novel JAK2 small molecule inhibitor SB1518 is being conducted in patients with relapsed Hodgkin (HL) and non-Hodgkin lymphomas (NHL). The primary objectives are to examine the safety and efficacy of SB1518 in this patient population. Patients are treated at four dose levels (100 mg, 200 mg, 300 mg, and 400 mg) orally daily without interruption.
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
2. S*BIO Completes US$26 Million Equity Financing
3. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
4. S*BIO Receives BioSpectrum Editors Choice, Emerging BioScience Company of Singapore Award
5. Novel Technology Breaks Through Cancer Pain
6. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
7. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
8. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
9. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
10. NIST team develops novel method for nanostructured polymer thin films
11. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... BOSTON , June 17, 2013 ... billion by 2018, accounting for nearly 16 percent of total ... Drug Report 2013 from Evaluate .   ... this growing segment of the pharmaceutical industry, Evaluate has enhanced ... fact-based orphan drug analysis with data fields for integrated US, ...
(Date:6/17/2013)... CLEVELAND , June 17, 2013 ... healthcare organizations in the country, recovered more than ... with the help of OnBase, Hyland Software,s ... with Hyland to provide a common revenue cycle ... billing systems that were in place for both ...
(Date:6/17/2013)... 2013 Research and ... addition of the "North America Injectable ... Microspheres, & Nanoparticles], Devices [Disposables & Reusable, ... Auto Injectors] & Therapeutics- Forecasts to 2017" ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
(Date:6/17/2013)... BEIJING , June 17, 2013 Yongye ... a leading developer, manufacturer, and distributor of crop nutrient ... ("PRC"), announced today that its common stock ... Monday, June 17, 2013 at 7:15 a.m. Eastern Time. ... Yongye,s common stock on Monday, March 18, 2013 following ...
Breaking Biology Technology:Evaluate Launches Enhanced Orphan Drug Intelligence 2Evaluate Launches Enhanced Orphan Drug Intelligence 3Cedars-Sinai Medical Center Recovers More Than $300 million in AR with Hyland Software's OnBase 2Cedars-Sinai Medical Center Recovers More Than $300 million in AR with Hyland Software's OnBase 3North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 2North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 3Yongye International, Inc. Announces Common Stock Will Resume Trading on the NASDAQ Stock Market on June 17, 2013 2Yongye International, Inc. Announces Common Stock Will Resume Trading on the NASDAQ Stock Market on June 17, 2013 3Yongye International, Inc. Announces Common Stock Will Resume Trading on the NASDAQ Stock Market on June 17, 2013 4
... , , KNOXVILLE and OAK ... Ridge Innovation Valley ( www.knoxvilleoakridge.com ) see the successful test of ... , The Innovation Valley is home to Oak Ridge National Laboratory ... at the forefront of applied carbon fiber research. , ...
... NEW YORK, Dec. 18 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. ... a pharmaceutical,company dedicated to improving health through the development, ... over the counter ("OTC"),products, today announced that 158 of ... Insurance Catalog (the "2009 NIC"). Of these, 82,are categorized ...
... Department of Energy,s Pacific Northwest National Laboratory have ... the Advancement of Science for their exceptional efforts ... PNNL honorees and the AAAS sections that elected ... Yuehe Lin, chemistry; Philip Rasch, atmospheric and hydrospheric ...
Cached Biology Technology:Boeing Flight Boosts Carbon Fiber Hopes, Knoxville-Oak Ridge Innovation Valley Poised 2Boeing Flight Boosts Carbon Fiber Hopes, Knoxville-Oak Ridge Innovation Valley Poised 3American Oriental Bioengineering Announces the Inclusion of 158 Drugs in China's National Insurance Catalog 2American Oriental Bioengineering Announces the Inclusion of 158 Drugs in China's National Insurance Catalog 36 PNNL scientists elected AAAS fellows 26 PNNL scientists elected AAAS fellows 3
(Date:6/17/2013)... University research associate has received a prestigious fellowship to ... the spread of malaria. , Bart Bryant, research associate ... National Research Service Award Individual Postdoctoral Fellowship, which provides ... State University researcher to receive the award and is ... an award. , Bryant, a university doctoral graduate in ...
(Date:6/17/2013)... populations are declining worldwide and a major cause is ... but a two-year study shows they can also die ... a tolerant carrier host that just spreads the disease. ... controlled experimental conditions, they found at least one strain ... Bd or a chytrid fungus, can be fatal to ...
(Date:6/16/2013)... for female sex workers in India reduce rates of ... University of Toronto study has found. , ... in the southern states of Andhra Pradesh, Karnataka, Maharashtra ... Jha from U of T,s Dalla Lana School of ... Health Research (CGHR), examined the impact of prevention among ...
Breaking Biology News(10 mins):NIH fellowship helps researcher fight malaria, understand mosquito immunity 2Bullfrogs may help spread deadly amphibian fungus, but also die from it 2HIV prevention among female sex workers in India reduces HIV and syphilis 2
... polymers (LCP) as a viable tool for use in ... of Alberta researchers, collaborating with colleagues at the Eindhoven ... Netherlands, have shown that LCP, when formed into a ... and patterned on a microscale. The research was published ...
... cell fate decisions for many types of developing cells, according to ... sheds light on a puzzling behavior. For some differentiating stem ... to a new choice. In response to the initial ... different cell types. It often requires a second signal for ...
... with a single injection into a vein holds promise ... University of Florida researchers report. , UF researchers used ... a form of muscular dystrophy that damages the heart. ... and found genes were readily absorbed by heart muscle ...
Cached Biology News:Polymers show promise for lab-on-a-chip technology 2Researchers map out networks that determine cell fate 2Researchers map out networks that determine cell fate 3UF scientists test improved gene therapy method for hereditary heart conditions 2UF scientists test improved gene therapy method for hereditary heart conditions 3UF scientists test improved gene therapy method for hereditary heart conditions 4
... Columns, 10. *SizeSep 400 Spun Columns: For ... pairs in length. - ... in distilled water containing 0.15% Kathon CG/IcP Biocide. ... base pairs. *Extremely useful in the ...
... Light Diagnostics Universal Amplicon Detection ... use in the qualitative detection ... by in vitro nucleic ... only; not to be used ...
... Purification Kit, 25 purifications. Allows ... probesProvides efficient removal of unincorporated CyDye ... with superior yields of labeled cDNA ... of cDNA labeled by either direct ...
... Kit, 50 purifications. Allows rapid purification ... removal of unincorporated CyDye label and ... yields of labeled cDNA probe. ... labeled by either direct incorporation or ...
Biology Products: